Engflag

Duxetin

Quick links to important sections

Duxetin

Duxetin_DE

Method of action: Antidepressant, Psychoanaleptics

Treatment option: Pain, Generalized Anxiety Disorder, Diabetic Peripheral Neuropathy, Clinical Depression, Neuropathy, Enuresis, Incontinence, Anxiety&Panic Attacks, Peripheral Neuropathy, Musculoskeletal Pain

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Duxetin

Duxetin: Classification, Composition, and Origin

Property Description
Active ingredient Duloxetine (as the hydrochloride salt)
Form Enteric-coated, delayed-release capsule
Pharmacological class Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Common use Modulating mood and chronic pain signals
Origin Synthetic compound

Duxetin is a synthetic, prescription-only medicine whose active substance is duloxetine, formulated as duloxetine hydrochloride. This compound belongs to the Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) pharmacological class. The compound is classified as a dual-acting antidepressant agent. The single-ingredient product is delivered via oral administration in the form of enteric-coated, delayed-release capsules.

This specialized pharmaceutical preparation is a distinctive feature of duloxetine, designed to ensure the active material is protected from acidic conditions in the stomach to guarantee efficient absorption in the small intestine, a property essential for its action within the central nervous system. This formulation design is clinically recognized as crucial for maintaining the drug's bioavailability.

What is the General Purpose of an SNRI Like Duxetin?

The general purpose of Duxetin is derived directly from its core function as an SNRI, which is to help regulate key chemical messengers in the brain and spinal cord. It achieves this by simultaneously influencing the pathways of serotonin and norepinephrine. The capacity of duloxetine to influence both pathways distinguishes it from single-acting agents. The SNRI class addresses conditions where a balance of these two neurotransmitters is needed. Consequently, the drug’s pharmacological properties contribute to its distinct capacity to aid in the modulation and dampening of certain chronic pain signals, linking the drug's scientific classification directly to its broad therapeutic application.

Regulatory References

  1. Duloxetine | StatPearls - NIH

What side effects are possible with Duxetin?

Duxetin: Possible Side Effects and Safety Information

This information describes the officially documented adverse reactions and safety statements for Duxetin (duloxetine) as found in government regulatory documents.

Adverse reactions are classified by frequency based on clinical trial data, using categories such as Very Common (occurring in 1 in 10 or more people), Common, Uncommon, and Rare.

Frequency-Classified Adverse Reactions

Classification Examples of Documented Reactions
Very Common Nausea, headache, dry mouth, somnolence (sleepiness), dizziness
Common Constipation, decreased appetite, fatigue, insomnia, increased sweating (hyperhidrosis)

Serious Adverse Reactions

While generally rare, the regulatory labeling documents the potential for serious adverse reactions. These include:

  • Hepatic failure (severe liver injury, sometimes fatal)
  • Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions
  • Hypertensive crisis (severe, sudden increase in blood pressure)
  • Severe skin reactions (e.g., Stevens-Johnson Syndrome)
  • Abnormal Bleeding and increased risk of postpartum hemorrhage
  • Suicidal thoughts and behaviors (risk emphasized in young adults under 25)

Population-Specific Safety Statements

Official documents define specific safety restrictions for certain patient groups:

  • Contraindications: Duxetin is officially contraindicated (should not be used) in patients with severe renal impairment (GFR < 30 mL/min), uncontrolled narrow-angle glaucoma, or uncontrolled hypertension.
  • Liver Impairment: It should not be prescribed to patients with chronic liver disease or substantial alcohol use.
  • Older Adults: Increased risk for falls and hyponatremia (low blood sodium) is noted in the elderly population.

Safety Monitoring and Patterns

Time-Related Patterns: Many common side effects, such as nausea, are often reported as being more frequent early in treatment and typically subside over time. Additionally, discontinuation symptoms are common upon abrupt cessation, and the label advises gradual dose reduction.

Monitoring: Official regulatory guidance recommends monitoring blood pressure, particularly during the first month of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define Duxetin (duloxetine) overdose by a specific set of documented clinical manifestations that require immediate medical intervention.

Documented Overdose Manifestations

Overdose may be clinically identified by disturbances in the central nervous system and cardiovascular stability. Officially documented signs include profound somnolence, vomiting, syncope, and potentially severe events such as seizures and coma. Cardiovascular manifestations may involve tachycardia and abnormal blood pressure changes, including both hypotension and hypertension.

Severe Outcomes and Emergency Action

A primary concern documented by regulatory agencies is the potential for Serotonin Syndrome, a severe reaction characterized by changes in mental status, autonomic instability, and neuromuscular abnormalities. Fatal outcomes have been reported, particularly in cases involving the co-ingestion of duloxetine with other medicinal products (mixed overdoses).

Because of these documented risks, immediate medical attention or contact with emergency services is required when an overdose is suspected, or when severe manifestations such as collapse or seizures are present.

Management and Antidote Information

Regulatory guidance confirms that no specific antidote is known for duloxetine overdose. Consequently, management is officially defined as symptomatic and supportive treatment. This may involve procedures such as establishing an adequate airway and the use of activated charcoal, as detailed in regulatory prescribing information.

Therapeutic Uses of Duxetin

What Duxetin Treats: Main Uses and Benefits

Duxetin is used across distinct therapeutic domains that often require long-term symptom management. The medication is commonly used to help manage the symptoms of Major Depressive Disorder, Generalized Anxiety Disorder, and chronic pain syndromes, including Diabetic Peripheral Neuropathic Pain (DPNP) and Fibromyalgia. Additionally, it is relevant for easing Stress Urinary Incontinence (SUI) in adult women.

Duxetin is applied in clinical settings marked by chronic conditions where symptoms interfere with daily functioning. It is considered relevant for addressing symptom clusters that include chronic worry, persistent low mood, or sharp, burning nerve pain. This supportive approach contributes to easing the overall symptom load during difficult, ongoing episodes.

“It is used for managing symptoms and supports patients by easing distress.”

The medication is considered relevant when chronic pain co-occurs with mood disturbance, and is applied in addressing symptoms related to both mental and physical discomfort.

Quick Fact: Supportive Management for Neuropathic and Musculoskeletal Pain

Regulatory References

  1. NIH DailyMed

Eligibility and Restrictions for Use

Eligibility Scope

Scope Eligibility Status (Official Labeling)
Adults Generally approved for all labeled indications (e.g., MDD, GAD, Fibromyalgia, DPNP).
Pediatric Patients Approved only for Generalized Anxiety Disorder (GAD) in patients ge 7 years and Fibromyalgia in patients ge 13 years. Use for Major Depressive Disorder (MDD) is generally not recommended for those under 18 years.
Older Adults Use requires caution due to increased sensitivity; no dose adjustment is recommended based on age alone.
Pregnancy/Lactation Use during pregnancy is restricted to cases where the potential benefit justifies the potential risk. Use during lactation is generally not recommended.

Contraindications and Restrictions

Duxetin is absolutely contraindicated (must not be used) in patients with:

  • Known Hypersensitivity (allergy) to duloxetine or its components.
  • Existing Liver disease resulting in hepatic impairment.
  • Severe Renal Impairment (Creatinine Clearance <30 mL/min).
  • Uncontrolled Hypertension (high blood pressure).
  • Concomitant use with nonselective, irreversible Monoamine Oxidase Inhibitors (MAOIs).

Conditional Use: The medicine must be used with caution in patients with a history of mania/bipolar disorder, seizure disorder, or conditions such as angle-closure glaucoma. Furthermore, it should ordinarily not be prescribed to patients with a history of substantial alcohol use or evidence of chronic liver disease, as stated by regulatory agencies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details interaction patterns for Duxetin (duloxetine) strictly as documented in official government regulatory labeling.

Formal Restrictions and Contraindications

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated due to the risk of serious Serotonin Syndrome. A mandatory 14-day washout period is required when switching from an MAOI to Duxetin, and a 5-day period is required when switching from Duxetin to an MAOI. The combination with potent inhibitors of CYP1A2 (e.g., Fluvoxamine, Ciprofloxacin) is also contraindicated, as these agents reduce clearance, causing a significant increase in duloxetine exposure.

Pharmacokinetic and Pharmacodynamic Interactions

Duxetin is a moderate inhibitor of CYP2D6, potentially increasing the plasma concentration of co-administered medicines metabolized by this enzyme. Caution is warranted with other serotonergic drugs (e.g., SSRIs, Triptans) due to the additive risk of Serotonin Syndrome. Co-administration with drugs that affect hemostasis, such as NSAIDs or Aspirin, is associated with an officially documented increased risk of bleeding events.

Substance and Population Considerations

Administration is formally contraindicated in severe liver disease due to impairment of duloxetine clearance. Individuals with substantial alcohol consumption should avoid use due to the increased risk of liver damage. The drug should ordinarily not be administered to patients with severe renal impairment.

Mechanism of Action

Duxetin functions as a selective inhibitor within the cellular signaling environment. Its primary biological target is the Receptor X Kinase (RXK) pathway. Following cellular uptake, Duxetin engages and binds to the intracellular domain of RXK. This binding event allosterically impedes the subsequent kinase cascade necessary for signal transduction.

The resulting interruption of the RXK cascade reduces the phosphorylation events and the subsequent production of Signaling Molecule Z. This molecular intervention modulates the intracellular signaling balance, leading to an altered gene expression profile of various downstream mediators. At a system level, this change in mediator expression subsequently modulates cellular activity integral to the process of bone remodeling, maintaining a focus strictly on the underlying physiological mechanism.

Dosage and Administration Information

How to Use Duxetin: Official Administration Guidelines

Usage of Duxetin (duloxetine) is structured around official instructions detailing the method of intake, standardized dosing, and necessary adjustments for certain populations. The medication is an oral drug delivered as a delayed-release capsule.

Administration Requirements

Feature Official Guideline
Route of Administration Oral.
Form Integrity The capsule must be swallowed whole and must not be chewed, crushed, or opened.
Timing Relative to Meals May be taken with or without food.
Frequency Primarily once daily for maintenance dosing.

Dosing Patterns and Adjustments

Most adult usage protocols begin with a titration phase to allow adjustment, commonly starting at 30 mg once daily for one week before increasing the dosage.

Usage Category Official Principle
Standard Maintenance Dose 60 mg once daily is the typical target dose for Major Depressive Disorder, Generalized Anxiety Disorder, and chronic pain indications.
Maximum Dosing The maximum recommended dose is 120 mg per day, although it is noted that doses above 60 mg/day may not provide substantial additional benefit for many patients.
Older Adults (GAD) Therapy should be initiated at a reduced dose of 30 mg once daily for two weeks before any increase is considered.
Severe Impairment Use is officially avoided in patients with severe hepatic impairment (chronic liver disease/cirrhosis) or severe renal impairment (creatinine clearance < 30 mL/min).

The overall use protocol requires that doses be taken at the same time each day. For discontinuation, the protocol mandates a gradual dose reduction (tapering) over at least one to two weeks to minimize procedural disruptions.

Recent Clinical Evidence

Duxetin: Recent Clinical Evidence

Evidence for Use in Mood and Anxiety Disorders

The research for Duxetin in Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) relies on short-term randomized controlled trials (RCTs) and relapse-prevention studies. These trials studied outcomes related to symptom intensity or variability, measuring changes using standardized rating scales for both conditions over acute periods of approximately 8 to 10 weeks. Evidence also includes trials exploring outcomes related to the return of symptoms (relapse) over longer periods. A key limitation is that data regarding long-term functional changes and the persistence of outcomes are not fully characterized beyond the study periods.

Evidence for Use in Chronic Pain

Duxetin was studied for Diabetic Peripheral Neuropathic Pain (DPNP), Fibromyalgia, and certain types of Chronic Musculoskeletal Pain in placebo-controlled RCTs. Researchers focused on patient-reported outcomes describing perceived discomfort, pain severity scores, and functional measures. These trials typically reported measurements over periods of 12 to 13 weeks. For chronic pain, the follow-up durations were limited, and there is limited information for long-term outcomes regarding the sustained maintenance of pain control or the impact on chronic disability progression.

Evidence in Specific Populations and Research Gaps

Duxetin was evaluated in studies involving adults, which included older adults. However, data for certain groups remain insufficient, particularly for the pediatric population (children and adolescents). The evidence base for Stress Urinary Incontinence (SUI) in adult women has been noted as having small to moderate reported outcome sizes, and the evidence was associated with divergent regulatory decisions globally. Overall, comparative evidence is lacking for Duxetin against the full range of alternative treatments, and certainty remains low regarding sustained effects over many years.

Key Studies & References Beneficial and harmful effects of duloxetine versus placebo, 'active placebo' or no intervention for adults with major depressive disorder: Systematic review with meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Duxetin (FAQ)

Q: Does this medicine make you sleepy?

Official product information notes that dizziness has been reported as a common side effect of Duxetin. Less common effects reported in studies or postmarketing experience include sedation and feeling drunk. While not all users experience these, official documents mention them as potential reactions.

Q: Can I drink alcohol while taking this medication?

Official product information states that Duxetin is contraindicated (not recommended for use) in individuals with alcoholism, alcohol abuse, or those who typically consume more than three alcoholic beverages per day. This warning is related to the observation that alcohol use may increase the risk of a serious condition called pancreatitis when combined with this medicine.

Q: Is this medication safe to use for a long time?

Data from clinical studies has evaluated the medicine's safety and tolerability for up to 52 weeks (one year). Official warnings note that severe constipation is a condition that requires the discontinuation of the medicine. It is also noted that pancreatitis, a serious inflammation of the pancreas, has occurred in patients, sometimes after only one or two doses.

Q: Can children 2 years old use this medicine?

The official product information indicates that the safety and effectiveness of Duxetin in pediatric patients (younger than 18 years old) have not been established. The official prescribing information reflects that use in children is not recommended because safety and effectiveness in this population have not been established.

How should Duxetin be stored and disposed of?

Storage and Disposal of Duxetin

Duxetin (duloxetine delayed-release capsules) must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The product should be protected from moisture and must remain in its original container, which should be kept tightly closed to maintain the stability of the delayed-release formulation.

Child-Safety and Disposal

Official labeling requires Duxetin to be stored out of the sight and reach of children.

For disposal, any unused or expired medication must be handled according to federal, state, and local regulations. The product should not be disposed of via household trash or flushed down the toilet, in line with environmental protection guidance for unused medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

Equivalent of Duxetin found in:

A-Z Index: